Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 5/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| As1940477 SCHEMBL20873909 | 1.00 | MAPK13 (1.00) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| As1940477 SCHEMBL4237689 | 1.00 | MAPK13 (1.00) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| As1940477 SCHEMBL13928941 | 1.00 | MAPK13 (1.00) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL4241440 | 0.92 | MAPK13 (0.84) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL4239820 | 0.90 | MAPK13 (0.82) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL4241286 | 0.90 | MAPK13 (0.82) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL4239771 | 0.90 | MAPK13 (0.82) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL29594284 | 0.90 | MAPK13 (0.82) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL29594201 | 0.90 | MAPK13 (0.82) | MAPK13MAPK11CYP2C9MAPK14MAPK12 | |
| SCHEMBL4712371 | 0.90 | MAPK11 (0.81) | MAPK13MAPK11CYP2C9MAPK14MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4653055-A2 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| CN-114401719-A | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3984537-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | MAPK13 62/4885MAPK11 82/4885CYP2C9 4483/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | MAPK13 62/4885MAPK11 82/4885CYP2C9 4483/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | MAPK13 3249/4885MAPK11 4517/4885CYP2C9 2207/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK13 23/4885MAPK11 26/4885CYP2C9 4152/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | MAPK13 60/4885MAPK11 133/4885CYP2C9 4590/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | MAPK13 49/4885MAPK11 146/4885CYP2C9 3089/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK13 303/4885MAPK11 857/4885CYP2C9 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.